Luye Pharma Group (HK:2186) has released an update. Luye Pharma Group has received approval from China’s National Medical ...

Rykindo is something of a pathfinder product for Luye Pharma, however, and will allow the Chinese company to build a commercial presence in the US antipsychotics market as it brings forward its ...

Luye Pharma Group (HK:2186) has released an update. Luye Pharma Group has successfully completed the issuance of US$100 million in convertible ...

Luye Pharma Group (HK:2186) has released an update. Luye Pharma Group has announced the issuance of $100 million in convertible bonds with a 5.85% interest rate due in 2025, aimed at enhancing its ...

Luye Pharma Group (HK:2186) has released an update. Luye Pharma Group has announced a revised closing date for its issuance of $100 million convertible bonds, now set for October 30, 2024.

Shandong Luye Pharmaceutical Co. Ltd. has divulged tachykinin NK3 receptor antagonists reported to be useful for the treatment of attention deficit hyperactivity disorder (ADHD), depression, pain, ...